83例局部晚期非小细胞肺癌同步放化疗临床分析（英文）.pdfVIP

Chinese-German Journal of Clinical Oncology January 2012, Vol. 11, No. 1, P1–P5 DOI 10.1007/s10330-011-0892-6 Clinical analysis of concurrent chemoradiotherapy in 83 patients with locally advanced non-small cell lung cancer Zhihua Sun, Qinfeng Li, Zhenyu Li, Yeshan Chen, Yao Jiang, Gang Wu Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China Received: 19 August 2011 / Revised: 20 September 2011 / Accepted: 25 October 2011 © Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2012 Abstract Objective: The purpose of this study was to evaluate the efficacy and safety of concurrent chemoradiotherapy (CCRT) in patients with locally advanced non-small cell lung cancer (LANSCLC). Methods: 83 cases of patients who have been diagnosed for locally advanced NSCLC by determined cytology or pathology were divided into two groups randomly, 42 patients in NP group and 41 patients in EP group. All patients accepted thoracic three-dimensional conformal radiotherapy (3D-CRT) and concurrent either NP chemotherapy in NP group or EP chemotherapy in EP group. 3D-CRT were started on day 1 in the first cycle of chemotherapy. Chemotherapy were carried out for 4 cycles, every cycle was 21 days. Thoracic radiotherapy adopted conventional fractionated irradiation with 15 MeV-X ray, a total dose of 60 Gy. Results: In 83 patients were evaluable, there were 5 cases complete regression to be observed, 29 cases had partial regression (PR), 7 cases with stable disease (SD) and 1 case with progression disease (PD) in NP group. CR 3 cases, PR 27 cases, SD 9 cases and PD 2 cases in EP group. The overall respon